행사 소개
What To Expect At The World Bispecific & T-Cell Engager Summit South Korea
The bispecific and T-cell engager space is buzzing with innovation, with the global focus shifting to first-in-class therapies that improve response rates and reduce dose-limiting toxicities. The race is now on to engineer smarter, safer, and more potent bispecifics and T-cell engagers, with innovators from Korea, including ABL Bio, Novelty Nobility, and Celltrion, turning to new strategies in antibody design to get there and capturing international attention and investment.
To accelerate this momentum, the inaugural World Bispecific & T-Cell Engager Summit South Korea will bring together global pioneers for the first and only industry-dedicated event in Korea focused on Bispecifics and TCEs. The program has been designed to spotlight co-stimulatory approaches, conditional activation, trispecifics and tetraspecifics, advanced antibody engineering, bispecific ADCs, novel targets, translational biology, T-cell engagers in autoimmune disease, and more, providing the tools to help establish Korea as a global powerhouse in this rapidly evolving field.
Whether you’re advancing candidates into the clinic, accelerating a bispecific pipeline, tackling translational hurdles, or seeking strategic partnerships, join 80+ global and local leaders, Directors, Heads, Scientists, and pioneering service providers to learn, collaborate, and shape the future of bispecific and T‑cell engager R&D in South Korea.
This event is part of the World Targeted Therapeutics Summit South Korea, so attendees will also have access to sessions for the 5th World ADC South Korea Summit and the inaugural World TPD & Induced Proximity Summit South Korea.
Placing Innovation First: Key Themes on the Agenda
혁신을 최우선으로: 주요 의제 핵심 주제
Co‑stimulation
Discover how AstraZeneca, Hanmi Pharmaceuticals and Celltrion are deploying co‑stimulatory mechanisms to fine‑tune potency, safety and durability, enabling higher dosing and expanding the therapeutic window
Conditional Activation
See how ABL Bio and AP Biosciences are engineering conditional T‑cell activation from TAA‑dependent 4‑1BB agonism to designs that avoid direct CD3 engagement to deliver safer, more selective therapies
Bispecific ADCs
Explore the emerging frontier where ADCs meet Bispecifics, boosting target specificity and reducing on‑tumor/off‑target toxicity. Case studies will unpack bsADC design principles, translational learnings and development strategies
Download the Official Agenda to Explore:
공식 아젠다를 다운로드하여 다음 내용을 확인하세요:
- Your One-Stop Forum to Develop Best-in-Class Bispecifics & T-Cell Engager-Based Therapeutics
- Insights from 20+ Korean-Based and International Speakers
- Unrivalled Networking Opportunities with Professionals Working on Bispecifics & T-Cell Engagers, ADCs, TPD & Induced Proximity
Attending Companies Include:
참석 기업 목록:
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.